Key clinical point: Among patients with HER2-mutated non–small cell lung cancer, treatment with trastuzumab deruxtecan has yielded a high objective response rate and favorable progression-free survival.
Major finding: The confirmed overall response rate was 61.9%, and the median progression-free survival was 16.0 months.
Study details: Interim results of DESTINY-Lung01, a phase 2 study of 42 patients with HER2-mutated non–small cell lung cancer.
Disclosures: The study was sponsored by Daiichi Sankyo Inc. Dr. Smit disclosed relationships with Daiichi Sankyo and other companies.
Smit EF et al. ASCO 2020, Abstract 9504.